Who
Mark Eisner
Director
Company insider
Files Form 4 as: Director, Jade Biosciences; Director, Zura Bio; EVP and Chief Medical Officer, Vir Biotechnology; EVP, Chief Medical Officer, Kyntra Bio.
In numbers
- Trades disclosed
- 49
- Buys
- 0
- Sells
- 11
- Bought
- $0
- Sold
- $770K
- Companies
- 4
- Companies where not an officer
- 2
- First trade
- 1 Dec 2020
- Last trade
- 25 Jun 2026
- Last filed
- 26 Jun 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 25 Jun 2026filed 26 Jun 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,675 at $0.00 | filing |
| 25 Jun 2026filed 26 Jun 2026 | JBIO Jade Biosciencesoption or derivative · Biotechnology | SEC FORM 4 Code A | —47,675 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 17 Jun 2026filed 22 Jun 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —51,000 at $0.00 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $19K1,889 at $9.82 | filing |
| 25 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $19K1,889 at $9.82 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $15K1,616 at $9.53 | filing |
| 24 Feb 2026filed 26 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $15K1,616 at $9.53 | filing |
| 23 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $16K2,089 at $7.45 | filing |
| 23 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $16K2,089 at $7.45 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —110,000 at $0.00 | filing |
| 22 Feb 2026filed 24 Feb 2026 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —55,000 at $0.00 | filing |
| 21 Feb 2026filed 24 Feb 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —37,812 at $0.00 | filing |
| 21 Feb 2026filed 24 Feb 2026 | ZURA Zura Biooption or derivative · Biotechnology | SEC FORM 4 Code A | —37,812 at $0.00 | filing |
| 17 Jul 2025filed 17 Jul 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $20K3,586 at $5.47 | filing |
| 15 Jul 2025filed 17 Jul 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Sold | $37K6,796 at $5.47 | filing |
| 22 Feb 2025filed 25 Feb 2025 | VIR Vir Biotechnologyoption or derivative · Biotechnology | SEC FORM 4 Code A | —80,000 at $0.00 | filing |
| 22 Feb 2025filed 25 Feb 2025 | VIR Vir BiotechnologyBiotechnology | SEC FORM 4 Code A | —40,000 at $0.00 | filing |
News
Vir Biotechnology (NASDAQ:VIR) Reaches New 12-Month High – Here's What HappenedVIR · tickerreport.com · 12 Oct 2026Vir Biotechnology (NASDAQ:VIR) vs. uniQure (NASDAQ:QURE) Critical ContrastVIR · dailypolitical.com · 11 Oct 2026Vir Biotechnology (NASDAQ:VIR) Price Target Raised to $22.00VIR · tickerreport.com · 10 Oct 2026
0 headlines in the last 90 days name Mark Eisner; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.